Skip to content

Verification of the safety and efficacy of Repetitive Transcranial Magnetic Stimulation for intractable epilepsy

Verification of the safety and efficacy of Repetitive Transcranial Magnetic Stimulation for intractable epilepsy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032210051
Enrollment
10
Registered
2021-06-01
Start date
2021-06-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory epilepsy refractory epilepsy

Interventions

rTMS is delivered by a MagPro R30 (Inter Reha Co.,Ltd., Tokyo, Japan) at 0.9 Hz with a stimulus intensity of 90% of resting motor threshold (RMT), basically two sets of 15 min stimulation per day for
rTMS

Sponsors

Kaito Nobuyoshi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients whose epileptic foci are identified by clinical or electroencephalographic data 2)Patients with uncontrollable seizures despite adequate medical therapy 3)Age at inclusion between 20 and 65 4)Regardless of patients sex 5)Patients who consent to join the present study with full understanding of the required and provided explanation 6)Patients who can visit or be admitted to the hospital according to the established schedule

Exclusion criteria

Exclusion criteria: 1)Patients with a severe heart disorder 2)Patients with head skin or scalp problems due to infection or radiotherapy 3)Patients with a mental disorder 4)Patients with diagnosed or suspected pregnancy 5)Patients identified as inadequate for the present study by the principal investigator 6)Patients with unstable health conditions that required emergency treatment prior to that for epilepsy

Design outcomes

Primary

MeasureTime frame
Occurrence of adverse events including predefined special interrest as shown below, 1)Novel patterns of paroxysmal abnormal electroencephalographic activity identified after manipulation 2)Hearing disturbance 3)Syncope 4)Focal pain at the place of magnetic stimuli 5)Mental deterioration 6)Functional disorders of the autonomic nerve system 7)New neurological symptoms and signs

Secondary

MeasureTime frame
To verify the efficacy of rTMS defined as shown below, 1)Decrease of seizure frequency 2)Improvement of higher brain functions 3)Decrease of abnormal discharges in electroencephalogram

Contacts

Public ContactNobuyoshi Kaito

The jikei University Hospital

kaito@jikei.ac.jp+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026